跳至主要内容
临床试验/CTRI/2024/12/078456
CTRI/2024/12/078456尚未招募不适用

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Non-comparator study to assess the efficacy and safety of AshwaVita Nutrition Powder in participants (children age between 1 to 15 years) with uncomplicated severe and moderate acute malnutrition

Rediskovar Innovative Products LLP1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2024年12月31日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
150
试验地点
1
主要终点
Assessment of change in Mid Upper Arm Circumference from baseline value

研究概览

简要总结

This study is a randomized, multiple-dose, two-arm, placebo-controlled, double blind, parallel design evaluating efficacy and safety of AshwaVita Nutrition Powder in 150 children with uncomplicated severe and moderate acute malnutrition for 12 weeks in India.

The primary outcome measures will be change in Mid Upper Arm Circumference, change in weight-for-height Z score & change in weight from baseline weight at week 12.

Overall, aim of the propose research is to validate efficacy & safety of AshwaVita Nutrition Powder in acute malnutrition.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant and Investigator Blinded

入排标准

年龄范围
1.00 Year(s) 至 15.00 Year(s)(—)
性别
All

入选标准

  • Child with Moderate or Severe Acute Malnutrition Child parent/legal representative willing to give a voluntary written informed consent and agree to come for regular follow up Child assent (verbal oral or written as applicable).

排除标准

  • Child having other acute and chronic systemic illnesses or requiring emergency management Child has a known hypersensitivity to any of the study drugs or excipients Child with developmental disorders like cerebral palsy or intellectual disability Child with an inborn error of metabolism, congenital abnormalities Child with a known history or present condition of allergic response to milk or any other ingredient of the formulation Child with neurobehavioral disorders like ADHD autism.

结局指标

主要结局

Assessment of change in Mid Upper Arm Circumference from baseline value

时间窗: Week 12

Assessment of change in weight-for-height Z score (as applicable)

时间窗: Week 12

Assessment of change in weight from baseline weight

时间窗: Week 12

次要结局

  • Assessment of change in BMI from baseline value(Assessment of change in weight-for-age Z score (as applicable) at week 12)

研究者

发起方
Rediskovar Innovative Products LLP
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Mahesh Rathod

Sardar Children Hospital

研究点 (1)

Loading locations...

相似试验

A clinical trial to study the effects of Nutrition... | 临床试验